ArticleCardiovascular drugs and therapy2024
Quantification of LDL-Cholesterol Corrected for Molar Concentration of Lipoprotein(a).
Article in Cardiovascular drugs and therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT02739984. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate Safety, Tolerability, and Efficacy of Evolocumab (AMG 145) on LDL-C in Subjects With Type 2 Diabetes Mellitus and Hypercholesterolemia/Mixed Dyslipidemia
Open the trial in the graphWho cites it
13 citing papers in PubMed, 19 citations in OpenAlex.
- Non-HDL Cholesterol as a Predictor of Coronary Atherosclerosis in South Asians: A Narrative Review.Current atherosclerosis reports · 2026Review
- Teenagers Cardiovascular Risk: The Underrated Role of Lipoprotein(a).Cardiovascular drugs and therapy · 2026Article
- Review
- Direct Lp(a)-C measurements provide evidence for Apo(a) isoform-dependent cholesterol composition of Lp(a).Journal of lipid research · 2026Article
- Analytical validation of a direct lipoprotein(a)-cholesterol assay.Journal of lipid research · 2026Article
- Serum lipoprotein(a) concentrations in presumably healthy Polish subjects in relation to age, sex, and cardiometabolic risk factors.Biochemia medica · 2026Article
- Lipoprotein(a) Concentration and Achieving Target Values of Low-Density Lipoprotein Cholesterol Calculated by Different Equations.Diseases (Basel, Switzerland) · 2026Article
- Lipoprotein(a) in Residual Cardiovascular Risk: Measurement Challenges, Assay Standardisation, and Clinical Implications.International journal of general medicine · 2026Review
- The interactions of Lipoprotein(a) with common cardiovascular risk factors in cardiovascular disease risk: evidence based on the UK Biobank.American journal of preventive cardiology · 2025Article
- Familial Hypercholesterolemia: Pitfalls and Challenges in Diagnosis and Treatment.Reviews in cardiovascular medicine · 2023Review
- A Real-World Exploration into Clinical Outcomes of Direct Oral Anticoagulant Dosing Regimens in Morbidly Obese Patients Using Data-Driven Approaches.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2023Observational
- Protective Effect of Sevoflurane Preconditioning on Cardiomyocytes Against Hypoxia/Reoxygenation Injury by Modulating Iron Homeostasis and Ferroptosis.Cardiovascular toxicology · 2023Article
- Lipoprotein (a) in the context of atherosclerosis: pathological implications and therapeutic perspectives in myocardial infarction. A narrative review.Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologieReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeCholesterol in lipoprotein(a) [Lp(a)-C] is commonly estimated as 30% of the measured Lp(a) mass. However, difficulties in the accurate measurement of Lp(a) mass, along with the inaccuracy of the 30% assumption, produce erroneous values when LDL-C is corrected for Lp(a) [LDL-C
methodsWe developed a new formula to calculate Lp(a)-C from the molar measurement of Lp(a), which is Lp(a) nmol/L × 0.077 = Lp(a)-C mg/dL. The calculated Lp(a)-C is subtracted from LDL-C to obtain LDL-C
resultsWith the conventional formula, approximately 7% of samples with low LDL-C resulted in negative LDL-C
conclusionThe new formula provides more reliable estimates of LDL-C
trial registrationClinicalTrials.gov NCT02739984.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.